01 / ACCESS
The right buyer may never see the asset.
Broad outbound campaigns and unsolicited decks can disappear into crowded S&E pipelines. TSCIP narrows the universe and engages teams for whom a strategic thesis can be articulated.
Selective Coverage · Active Field BD · Transaction Readiness
From Clinical Signal to Active, One-on-One Pharma Engagement.
TSCIP does not stop at a desk-based assessment. We select clinical-stage oncology assets with a credible buyer thesis, map the relevant pharma Search & Evaluation, External Innovation and BD teams, engage them one-on-one, and convert de-identified field outputs into the evidence, development and capital actions needed to improve transaction readiness.
Why TSCIP
S&E teams are overloaded. Asset owners need more than another strategic report.
High-quality oncology opportunities compete with a large volume of inbound outreach. TSCIP differentiates selected assets by doing the upstream work: defining buyer fit, approaching the relevant teams directly and learning what is required for action.
02 / DECISION
Interest often stops at an unstated requirement.
TSCIP uses direct field engagement to determine whether contribution, patient selection, safety, durability, development design or another issue is preventing action.
03 / EXECUTION
Feedback has value only if it changes the next move.
De-identified field outputs are returned to the asset owner and used to reshape evidence generation, development priorities, transaction positioning and capital-to-inflection.
How TSCIP works
Select → Map → Engage → Synthesize → Convene → Advance.
TSCIP is deliberately selective because active field BD only works if buyers learn that an asset brought forward by TSCIP has already been screened for strategic relevance.
01
Select
TSCIP admits a limited set of assets where the science, rights position, strategic fit and buyer universe support credible field engagement. Coverage is not a paid listing.
02
Map
TSCIP develops a focused counterparty map around portfolio context, disease strategy, therapeutic backbones, development needs and transaction logic.
03
Engage
TSCIP conducts targeted, one-on-one outreach to relevant Search & Evaluation, External Innovation, BD and franchise teams using owner-authorized materials.
04
Synthesize
Direct field feedback and private platform activity are converted into de-identified evidence requirements, objections, diligence questions and conditions for advancement.
05
Convene
Where buyer interest warrants it, TSCIP facilitates direct buyer-owner discussions and buyer-specific Strategic Asset Reviews featuring a small pre-vetted slate.
06
Advance & Re-engage
Field outputs reshape evidence, development, positioning and capital-to-inflection. TSCIP then returns to mapped counterparties as the asset becomes more transaction-ready.
Confidential by design
Confidential engagement. Direct market access. Decision intelligence.
TSCIP actively engages relevant pharma teams while protecting the conditions required for candid buyer review. Asset owners receive de-identified, synthesized field outputs that show what is blocking or enabling action—not a surveillance feed of individual buyers.
Buyer confidentiality remains protected
Searches, views, saves, passes, named feedback and company-specific private requirements remain confidential unless the counterparty authorizes disclosure. TSCIP converts those interactions into owner-facing transaction-readiness intelligence.
The execution layer
TSCIP does the field work.
The core deliverable is not a diagnosis delivered from the desk. TSCIP stays in the loop from counterparty selection through outreach, feedback synthesis, qualified buyer access and re-engagement.
What active coverage means.
For an admitted asset, TSCIP develops the strategic thesis with the owner and then tests that thesis with the market. The resulting field intelligence is used to continually improve the asset's transaction readiness.
Buyer meetings are qualification-driven, not guaranteed access.
TSCIP facilitates direct interaction when its field work and the buyer's own review support a credible strategic fit.
TSCIP facilitates direct interaction when its field work and the buyer's own review support a credible strategic fit.
01
Counterparty mappingIdentify the pharma teams whose portfolio, strategy and development needs make the asset relevant.
02
One-on-one S&E / BD outreachApproach relevant teams with a defined strategic thesis rather than a generic company pitch.
03
De-identified field feedbackSynthesize evidence gaps, diligence concerns, objections and conditions for advancement.
04
Qualified direct engagementFacilitate buyer-owner discussions when the buyer chooses to move from private review to direct interaction.
05
Strategic Asset ReviewsWhere appropriate, convene a buyer-specific, invitation-only review of a small slate—typically four to five pre-vetted assets presented sequentially by their owners.
06
Re-engagementReturn to the field as evidence, development strategy or transaction terms evolve.
Capital-to-inflection
Finance the evidence the field says matters.
When field engagement identifies a solvable evidence gap, TSCIP can help define the amount, timing and form of capital needed to reach that decision point. Capital supports the transaction-readiness loop; it is not a substitute for buyer validation.
Strategic investment
Co-development funding
Regional licensing
Option structures
Royalty monetization
Asset-level financing
Structured debt
Role boundary: TSCIP and Nectid provide strategic advisory, business-development
execution, diligence and decision-support services. They are not broker-dealers, placement agents,
investment banks or securities intermediaries; they do not offer or sell securities, handle investor
funds, or receive transaction-based compensation for securities placements.
Who TSCIP serves
Selective access on both sides of the transaction.
TSCIP is useful only if buyers trust the quality of what reaches them and asset owners receive actionable field intelligence rather than another list of theoretical counterparties.
Asset owners
TSCIP acts as an execution partner—developing the buyer thesis, taking it into the field, returning de-identified decision requirements and helping the owner act on them.
- Selective TSCIP coverage
- Counterparty mapping
- One-on-one S&E / BD outreach
- De-identified field feedback
- Evidence and development gates
- Capital-to-inflection
- Qualified direct buyer engagement
- Strategic Asset Review opportunities
- Re-engagement and transaction readiness
Pharma & strategic buyers
Buyers can privately review curated assets or receive thesis-led outreach from TSCIP when an asset appears relevant to their portfolio and strategic priorities.
- Pre-screened clinical-stage opportunities
- Buyer-specific strategic thesis
- Private platform review
- No owner-side buyer surveillance
- Confidential decision requirements
- Invitation-only Strategic Asset Reviews
- Direct engagement only when desired
Development-capital providers
Owner-authorized opportunities can be reviewed when a defined evidence tranche creates a credible value inflection and the use of capital is clear.
- Field-informed evidence requirement
- Defined use of capital
- Evidence-linked milestone
- Owner-authorized visibility
- Decision-focused diligence
- No securities placement by TSCIP
TSCIP worked case · PDS0301
From a recurring evidence gap to milestone-linked strategic financing.
PDS0301 illustrates the TSCIP model: repeated strategic evaluations converged on a specific contribution question, the development path was reframed around that issue, and capital was aligned with the next evidence milestone.
Public outcome updated September 14, 202601
Direct field engagement identified a recurring evidence issue
TSCIP did not infer the central gate from a desk review alone. Through direct BD engagement with relevant counterparties, de-identified feedback repeatedly converged on the need for clearer evidence of PDS0301's independent contribution to observed combination activity.
02
Field outputs were converted into an evidence gate
Rather than treating every counterparty response as an isolated BD outcome or defaulting to broad additional development, the recurring requirement was translated into a bounded evidence and late-stage development path.
03
Development and capital were framed around the inflection
The owner-facing transaction-readiness plan was reshaped around the recurring field requirement. Development and capital were organized around reaching a defined milestone that could close the strategic evidence gap rather than simply extending runway.
04
Public outcome: $11.3M initial close; up to $22.3M PIPE
PDS Biotech announced the financing on September 8 and completed the initial closing on September 14, 2026. The initial closing generated approximately $11.3 million in gross proceeds; the transaction provides for an additional $11 million milestone closing tied to submission of a registrational Phase 3 protocol for PDS0301, for total potential proceeds of approximately $22.3 million. Dr. Patrick Soon-Shiong and James Banaag joined the PDS Biotech board at the initial closing, and NantWorks received a one-year exclusive right to negotiate an exclusive license to PDS0101.
Important context: Public financing terms above are based on PDS Biotech's September 8 announcement and September 14, 2026 initial-closing update. That announcement does not attribute the financing to TSCIP.
The description of TSCIP's role reflects the TSCIP engagement and is presented to illustrate
the workflow; it should not be read as a claim that TSCIP was the sole cause of the financing.
Additional transaction experience
A longer history of translating differentiated assets into strategic value.
TSCIP builds on Nectid's prior experience creating therapeutic IP, positioning it for a strategic counterparty and carrying that work into a completed transaction.
Nectid-originated therapeutic IP → Grünenthal GmbH
A patent portfolio originating from Nectid was later acquired by Grünenthal. The historical precedent matters because it reflects the same discipline behind TSCIP today: differentiated thesis, defensibility, strategic fit and transaction execution.
Public transaction
2011
About TSCIP
Decision infrastructure for oncology transactions.
TSCIP
A confidential oncology transaction practice developed and operated by Nectid
TSCIP combines clinical-asset intelligence with active biotechnology business development: buyer-specific mapping, one-on-one field outreach, confidential buyer review, de-identified decision intelligence and evidence-to-transaction execution.
It is intentionally selective rather than an open marketplace. Assets enter coverage only when TSCIP believes a credible buyer thesis and substantive field engagement are possible. Buyer-side activity remains private unless a counterparty explicitly chooses to engage.
TSCIP supports licensing, options, co-development, strategic investment, financing, carve-outs and other transaction paths while keeping its internal scoring and decision architecture proprietary.
TSCIP is a proprietary practice of Nectid.
Explore TSCIP
Public principles. Proprietary decision engine.
These pages explain the TSCIP category, participant model and public proof points. Internal scoring, counterparty logic, private buyer activity and evidence-design rules remain confidential.
What is TSCIP?
A concise definition of the Tumor-State Combination Intelligence Platform and how it differs from a marketplace.
For Asset Owners
How decision-grade evidence, transaction readiness and capital-to-inflection fit together.
For Pharma
Private review of curated clinical-stage oncology opportunities without buyer-side surveillance.
Strategic Asset Reviews
How TSCIP can convene a small, buyer-specific slate of pre-vetted assets after platform review and field qualification.
Capital-to-Inflection
Why the financing requirement should be defined by the strategic evidence milestone it is meant to purchase.
PDS0301 Case Study
A worked application of the TSCIP model with a separately verifiable public financing outcome.
Contact
Have an asset that needs the right buyers—not another counterparty list?
Start with the asset, its current evidence and the transaction objective. TSCIP will assess whether there is a credible buyer universe and whether active field coverage is warranted. Initial conversations should remain non-confidential until both sides agree otherwise.